Gastrointestinal Agents : Agents Used in Peptic Ulcer Disease : H2 Receptor Antagonists
ORANI1 “Ranidine FC tablet” 150 mg/tab
ORANI2 “Ranitidine FC tablet” 150 mg/tab
適應症：十二指腸潰瘍、胃潰瘍、邊緣性之消化性潰瘍、逆流性食道炎、高濃度胃酸分泌症候群。
Usual dose:
Duodenal or gastric ulcer:
Adult: 150 mg bid or 300 mg hs; maintenance, 150 mg hs.
Pediatric (>= 1 mon): 2-4 mg/kg bid, max. 300 mg/day; maintenance, 2-4 mg/kg qd, max. 150mg/day.
Erosive esophagitis:
Adult: initial, 150 mg qid; maintenance, 150 mg bid.
Pediatric (>= 1 mon): initial, 5-10 mg/kg/day in 2 divided doses.
Gastroesophageal reflux disease:
Adult: 150 mg bid.
Pediatric (>= 1 mon): 5-10 mg/kg/day in 2 divided doses.
Hypersecretory conditions:
Adult: 150 mg bid, up to 6 gm/day have been used in p’ts with severe disease.
Indigestion, Non-ulcer:
Adult: 75-150 mg qd-bid, max. 300 mg/day
Stress ulcer, Prophylaxis:
Adult: 150 mg NG or PO bid.
Zollinger-Ellison syndrome:
Adult: PO 150 mg bid; up to 6 gm/day have been used in p’ts with severe disease.
Precaution:
Neonates, very low birth weight (401-1,500 gm); increased risk of developing necrotizing enterocolitis.
Adverse effect:
Common: constipation, diarrhea, nausea, vomiting, abdominal pain, bradyarrhythmia, headache, fatigue, dizziness, insomnia, somnolence.
Serious: anemia, thrombocytopenia, pancreatitis.
健保使用規範：同aluzaine。